target-competition

name	target-competition
description	Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
category	Competitive Intelligence
tags	["competition","landscape","pipeline","differentiation","market"]
version	1.0.0
author	Drug Discovery Team
dependencies	["drugbank","chembl","pharma-projects","citeline"]

Target Competition Skill

Comprehensive competitive landscape analysis for targets.

Quick Start

/target-compete EGFR --full
/competition "KRAS G12C" --include pipeline,patents,market
/landscape --target "PD-1" --by-phase

Competition Dimensions

1. Approved Drugs

Metric	Analysis
Number approved	Competitive intensity
Classes/mechanisms	Differentiation opportunities
First-in-class	Innovation level
Generics/biosimilars	Erosion risk
Market share leaders	Key competitors

2. Pipeline Drugs

Metric	Analysis
Phase 3	Near-term competition
Phase 2	Mid-term competition
Phase 1	Future competition
Novel mechanisms	Innovation potential

3. Company Coverage

Metric	Analysis
Big Pharma	Institutional interest
Biotech	Innovation sources
Emerging markets	Global competition

4. Patent Landscape

Metric	Analysis
Active patents	IP barriers
Expiration timeline	FTO timeline
White space	Opportunity areas

Output Structure

# Target Competition: KRAS G12C

## Competitive Landscape Summary

| Dimension | Assessment |
|-----------|------------|
| Approved drugs | 2 (Sotorasib, Adagrasib) |
| Pipeline drugs | 15 |
| Active companies | 18 |
| Patent density | Medium |
| Market maturity | Early-growth |

**Overall Competition**: Medium-High

## Approved Drugs

| Drug | Company | Approval Year | Sales (2023) | Market Share |
|------|---------|--------------|---------------|--------------|
| Sotorasib | Amgen | 2021 | $0.8B | 45% |
| Adagrasib | Mirati | 2022 | $0.2B | 15% |
| Others (off-label) | Various | - | $0.5B | 40% |

## Pipeline Analysis

### Phase 3

| Drug | Company | Differentiation | Timeline |
|------|---------|-----------------|----------|
| GDC-6036 | Gilead | CNS-penetrant | 2025 |
| JDQ443 | J&J | Combination | 2026 |

### Phase 2

| Drug | Company | Differentiation |
|------|---------|-----------------|
| RMC-6236 | Revolution | Oral macrocycle |
| BI 1701963 | Boehringer | Pan-KRAS |

### Phase 1

| Drug | Company | Novel Mechanism |
|------|---------|-----------------|
| 4 compounds | Various | Degraders |
| 3 compounds | Various | Allosteric |

## Company Analysis

### Big Pharma Activity

| Company | Pipeline | Strategy |
|----------|----------|----------|
| Amgen | 2 assets | Market leader |
| Mirati | 2 assets | Innovation |
| J&J | 3 assets | Multiple approaches |
| Roche | 2 assets | Combinations |

### Biotech Activity

| Company | Pipeline | Focus |
|----------|----------|-------|
| Revolution Medicine | 2 assets | Oral macrocycle |
| Kura Oncology | 1 asset | Selective inhibitor |
| BridgeBio | 2 assets | Different indications |

## Patent Landscape

| Metric | Value |
|--------|-------|
| Active patents (US) | 45 |
| Key patents expiring | 2033-2037 |
| Freedom to operate | Challenging |
| White space | Allosteric, degraders |

## Differentiation Opportunities

### Unmet Needs

1. **CNS penetration**: Current drugs don't reach brain mets
2. **Resistance mutations**: G12D, Y96D emerging
3. **Combination therapy**: With SHP2, SOS1
4. **Pan-KRAS**: Beyond G12C



| Area | Competition | Opportunity |
|------|-------------|------------|
| CNS-penetrant | Low | High |
| G12D inhibitors | Medium | Medium |
| Pan-KRAS | Medium | Medium |
| Degraders | Low | High (early) |
| Allosteric | Low | Medium |

2020: No approved drugs 2021: Sotorasib approval (first-in-class) 2022: Adagrasib approval (second-in-class) 2023-2025: Generics, biosimilars enter 2026+: Next-generation launch (CNS, combinations)

### Future Outlook

| Year | Event | Impact |
|------|--------|--------|
| 2025 | GDC-6036 launch | CNS opportunity |
| 2027 | Key patents expire | Generic entry |
| 2028 | Multiple 4th-gen | Market fragmentation |

## Strategic Recommendations

### For New Entrants

**Avoid**: Me-too G12C inhibitors (crowded)

**Consider**:
- CNS-penetrant molecules
- Resistance mutation coverage
- Novel mechanisms (degraders, covalent allosteric)
- Combination approaches

**Differentiation Strategies**:
1. **CNS penetration**: Brain metastasis indication
2. **Pan-KRAS**: Broad mutation coverage
3. **Combination-first**: Co-develop with SHP2/SOS1
4. **Resistance-focused**: Target emerging mutations

Competition Scoring

Market Maturity Index

Score	Description	Strategy
1	Novel target, no competition	First-in-class opportunity
2	Early competition	Fast follow opportunity
3	Multiple approved	Differentiation needed
4	Crowded, generics	Avoid or niche focus

Competitive Intensity

Dimension	Weight	Score
Approved drugs	30%	3/5
Pipeline diversity	25%	4/5
Patent density	20%	3/5
Company interest	15%	5/5
Innovation rate	10%	4/5

Overall: 3.8/5 (High competition)

Running Scripts

# Full competitive analysis
python scripts/target_competition.py KRAS --full

# Pipeline only
python scripts/target_competition.py EGFR --pipeline

# Patent landscape
python scripts/target_competition.py ALK --patents

# Company breakdown
python scripts/target_competition.py BRAF --companies

Reference

• reference/pipeline-analysis.md - Pipeline analysis methods
• reference/patent-landscape.md - Patent landscape reference

Best Practices

1. Include off-label: Approved drugs used in other indications
2. Track discontinued: Why did programs fail?
3. Assess innovation quality: Not all Phase 1s equal
4. Monitor startups: Often most innovative
5. Check conference abstracts: Early pipeline visibility

Common Pitfalls

Pitfall	Solution
Ignoring off-label use	Include real-world usage
Over-counting pipeline	Track active programs only
Missing discontinued	Check for terminated trials
Late-stage blind spot	Monitor conference abstracts
Geographic bias	Include China, Japan, EU